Neurophysiology and psychobiology of the placebo response

Current Opinion in Psychiatry

Volumn 21, Issue 2, 2008, Pages 189-195

  Klosterhalfen, Sibylle ^a   Enck, Paul ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Brain imaging; Clinical trials; Depression; Neurophysiology; Pain; Placebo response

Indexed keywords

BRAIN RADIOGRAPHY; BRAIN SCINTISCANNING; CLINICAL STUDY; CONCEPTUAL FRAMEWORK; CONDITIONING; DEPRESSION; ETHICS; HUMAN; IMAGING; MEDICAL RESEARCH; NEUROPHYSIOLOGY; PAIN; PATIENT CARE; PLACEBO EFFECT; PSYCHOBIOLOGY; REVIEW; STATISTICAL ANALYSIS;

BRAIN; CHOLECYSTOKININ; DEPRESSIVE DISORDER, MAJOR; DOPAMINE; HUMANS; PLACEBO EFFECT; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, OPIOID, MU;

EID: 40349094461     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/YCO.0b013e3282f50c36     Document Type: Review

References (71)

1. Enck P, Klosterhalfen S. The placebo response in functional bowel disorders: perspectives and putative mechanisms. Neurogastroenterol Motil 2005; 17:325-331.
2. Benedetti F, Pollo A, Lopiano L, et al. Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. J Neurosci 2003; 23:4315-4323.
3. Klinger R, Soost S, Flor H, Worm M. Classical conditioning and expectancy in placebo hypoalgesia: a randomized controlled study in patients with atopic dermatitis and persons with healthy skin. Pain 2007; 128:31-39.
4. Colloca L, Benedetti F. How prior experience shapes placebo analgesia. Pain 2006; 124:126-133.
5. Vase L, Riley JL 3rd, Price DD. A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia. Pain 2002; 99:443-452.
6. Chey WD, Chey WY, Heath AT, et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2004; 99:2185-2203.
7. Petrovic P, Kalso E, Petersson KM, Ingvar M. Placebo and opioid analgesia: imaging a shared neuronal network. Science 2002; 295:1737-1740.
8. Wager TD, Rittling JK, Smith EE, et al. Placebo-induced changes in fMRI in the anticipation and experience of pain. Science 2004; 303:1162-1167.
9. Pariente J, White P, Frackowiak RS, Lewith G. Expectancy and belief modulate the neuronal substrates of pain treated by acupuncture. Neuroimage 2005; 25:1161-1167.
10. Zubieta JK, Bueller JA, Jackson LR, et al. Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. J Neurosci 2005; 25:7754-7762.
11. Bingel U, Lorenz J, Schoell E, et al. Mechanisms of placebo analgesia: rACC recruitment of a subcortical antinociceptive network. Pain 2006; 120:8-15.
12. Kong J, Gollub RL, Rosman IS, et al. Brain activity associated with expectancy-enhanced placebo analgesia as measured by functional magnetic resonance imaging. J Neurosci 2006; 26:381-388.
13. Wager TD, Scott DJ, Zubieta JK. Placebo effects on human μ-opioid activity during pain. Proc Natl Acad Sci U S A 2007; 104:11056-11061. This important paper identifies - by connectivity analysis of fMRI data - two major cortical networks that contribute to the placebo response in experimental pain: one that processes the noxious stimulus and one that is activated in anticipation of pain; both are based on m-opioid activity, but show individual variation.
14. Nemoto H, Nemoto Y, Toda H, et al. Placebo analgesia: a PET study. Exp Brain Res 2007; 179:655-664.
15. de la Fuente-Fernandez R, Ruth TJ, Sossi V, et al. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001; 293:1164-1166.
16. Leuchter AF, Cook IA, Witte EA, et al. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry 2002; 159:122-129.
17. Mayberg HS, Silva JA, Brannan SK, et al. The functional neuroanatomy of the placebo effect. Am J Psychiatry 2002; 159:728-737.
18. Hunter AM, Leuchter AF, Morgan ML, et al. Neurophysiologic correlates of side effects in normal subjects randomized to venlafaxine or placebo. Neuropsychopharmacology 2005; 30:792-799.
19. Hunter AM, Leuchter AF, Morgan ML, Cook IA. Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression. Am J Psychiatry 2006; 163:1426-1432.
20. Lieberman MD, Jarcho JM, Berman S, et al. The neural correlates of placebo effects: a disruption account. Neuroimage 2004; 22:447-455.
21. Craggs JG, Price DD, Verne GN, et al. Functional brain interactions that serve cognitive-affective processing during pain and placebo analgesia. Neuroimage 2007; 38:720-729. This important paper investigated the brain processes of visceral nociceptive stimuli in female patients with IBS and shows that two placebo analgesia networks (one for nociceptive processing and one for affective processing) operate in a self-reinforcing feedback loop to maintain placebo analgesia.
22. Fricchione G, Stefano GB. Placebo neural systems: nitric oxide, morphine and the dopamine brain reward and motivation circuitries. Med Sci Monit 2005; 11:54-65.
23. Colloca L, Benedetti F. Placebos and painkillers: is mind as real as matter? Nat Rev Neurosci 2005; 6:545-552.
24. Beauregard M. Mind does really matter: evidence from neuroimaging studies of emotional self-regulation, psychotherapy, and placebo effect. Prog Neurobiol 2007; 81:218-236. This review paper summarizes and links neuroimaging studies in the field of psychophysiology (emotion), psychotherapy, and the placebo effect and proposes a translational concept of psycho-neural understanding
25. Lidstone SC, Stoessl AJ. Understanding the placebo effect: contributions from neuroimaging. Mol Imaging Biol 2007; 9:176-185. This review paper summarizes the current imaging literature of the placebo response specifically in Parkinson's disease and proposed the relevance of an endogenous striatum dopaminergic reward system.
26. Cavanna AE, Strigaro G, Monaco F. Brain mechanisms underlying the placebo effect in neurological disorders. Funct Neurol 2007; 22:89-94.
27. Martikainen IK, Hagelberg N, Mansikka H, et al. Association of striatal dopamine D2/D3 receptor binding potential with pain but not tactile sensitivity or placebo analgesia. Neurosci Lett 2005; 376:149-153.
28. Chung SK, Price DD, Verne GN, Robinson ME. Revelation of a personal placebo response: its effects on mood, attitudes and future placebo responding. Pain 2007; 132:281-288.
29. Scott DJ, Stohler CS, Egnatuk CM, et al. Individual differences in reward responding explain placebo-induced expectations and effects. Neuron 2007; 55:325-336. This important paper associates placebo analgesia as measured by PET dopamine binding with individual responsiveness to a monetary reward game (in an fMRI paradigm) to allow assessment of individual variation in placebo analgesia formation.
30. Zubieta JK, Yau WY, Scott DJ, Stohler CS. Belief or need? Accounting for individual variations in the neurochemistry of the placebo effect. Brain Behav Immun 2006; 20:15-26.
31. Matre D, Casey KL, Knardahl S. Placebo-induced changes in spinal cord pain processing. J Neurosci 2006; 26:559-563.
32. Watson A, El-Deredy W, Vogt BA, Jones AK. Placebo analgesia is not due to compliance or habituation: EEG and behavioural evidence. Neuroreport 2007; 18:771-775.
33. Paulson PE, Minoshima S, Morrow TJ, Casey KL. Gender differences in pain perception and patterns of cerebral activation during noxious heat stimulation in humans. Pain 1998; 76:223-229.
34. Berman S, Munakata J, Naliboff BD, et al. Gender differences in regional brain response to visceral pressure in IBS patients. Eur J Pain 2000; 4:157-172.
35. Sabatinelli D, Flaisch T, Bradley MM, et al. Affective picture perception: gender differences in visual cortex? Neuroreport 2004; 15:1109-1112.
36. Gizewski ER, Krause E, Karama S, et al. There are differences in cerebral activation between females in distinct menstrual phases during viewing of erotic stimuli: a fMRI study. Exp Brain Res 2006; 174:101-108.
37. Flaten MA, Aslaksen PM, Finset A, et al. Cognitive and emotional factors in placebo analgesia. J Psychosom Res 2006; 61:81-89.
38. Kallai I, Barke A, Voss U. The effects of experimenter characteristics on pain reports in women and men. Pain 2004; 112:142-147.
39. White P, Lewith G, Hopwood V, Prescott P. The placebo needle, is it a valid and convincing placebo for use in acupuncture trials? A randomised, single-blind, cross-over pilot trial. Pain 2003; 106:401-409.
40. Klosterhalfen S, Kellermann S, Pan F, et al. The effects of ethnicity and gender on motion sickness susceptibility. Aviat Space Environ Med 2005; 76:1051-1057.
41. Klosterhalfen S, Kellermann S, Braun S, et al. Women respond to conditioning, and men to suggestion of nausea. Gastroeenterology 2007; 132:A133f.
42. Klosterhalfen S, Pan F, Kellermann S, Enck P. Gender and race as determinants of nausea induced by circular vection. Gender Med 2006; 3:236-242.
43. Fucito LM, Juliano LM. Effects of instructions on responses to the nicotine patch: a laboratory study. Psychopharmacology (Berl) 2007; 194:475-483.
44. Levine ME, Stern RM, Koch KL. The effects of manipulating expectations through placebo and nocebo administration on gastric tachyarrhythmia and motion-induced nausea. Psychosom Med 2006; 68:478-486.
45. Meissner K, Gluender H, Mitzdorf U. Placebo effects on gastric slow wave frequency. Psychophysiology 2005; 42:S15-S16.
46. Weihrauch TR. Placebo treatment is effective differently in different diseases - but is it also harmless? A brief synopsis. Sci Eng Ethics 2004; 10:151-155.
47. Rief W, Avorn J, Barsky AJ. Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects. Arch Intern Med 2006; 166:155-160.
48. Benedetti F, Lanotte M, Lopiano L, Colloca L. When words are painful: unraveling the mechanisms of the nocebo effect. Neuroscience 2007; 147:260-271. This important paper is the first comprehensive review on the nocebo phenomenon and postulates similar mechanisms (expectations, conditioning) for both.
49. Benedetti F, Arduino C, Costa S, et al. Loss of expectation-related mechanisms in Alzheimer's disease makes analgesic therapies less effective. Pain 2006; 121:133-144.
50. Benedetti F, Amanzio M, Vighetti S, Asteggiano G. The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect. J Neurosci 2006; 26:12014-12022.
51. Patel SM, Stason WB, Legedza A, et al. The placebo effect in irritable bowel syndrometrials: a meta-analysis. Neurogastroenterol Motil 2005; 17:332-340.
52. Pitz M, Cheang M, Bernstein CN. Defining the predictors of the placebo response in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3:237-247.
53. Dorn SD, Kaptchuk TJ, Park JB, et al. A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome. Neurogastroenterol Motil 2007; 19:630-637. This metaanalysis reports that complementary and alternative medicine studies in IBS report a placebo response of similar size (40%) to conventional drug studies.
54. Fulda S, Wetter TC. Where dopamine meets opioids: a meta-analysis of the placebo effect in RLS treatment studies. Brain 2007; 11 October [Epub ahead of print]. This metaanalysis reports that the magnitude of the placebo response in restless-leg syndrome across 24 randomized controlled trials is 40%, but varies with outcomes chosen.
55. Sysko R, Walsh BT. A systematic review of placebo response in studies of bipolar mania. J Clin Psychiatry 2007; 68:1213-1217. This systematic review reports the placebo response rates in bipolar mania and depression to be around 30% across 21 placebo-controlled studies.
56. Macedo A, Banos JE, Farre M. Placebo response in the prophylaxis of migraine: a meta-analysis. Eur J Pain 2008; 12:68-75.
57. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002; 287:1840-1847.
58. Macedo A, Farré M, Baños JE. A meta-analysis of the placebo response in acute migraine and how this response may be influenced by some of the characteristics of clinical trials. Eur J Clin Pharmacol 2006; 62:161-172.
59. Kobak KA, Kane JM, Thase ME, Nierenberg AA. Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? J Clin Psychopharmacol 2007; 27:1-5.
60. Gøtzsche PC, Hróbjartsson A, Maric K, Tendal B. Data extraction errors in meta-analyses that use standardized mean differences. JAMA 2007; 298:430-437. This important meta-metaanalysis reports data extraction errors in the range of up to 70% (in seven of 10 metaanalyses included).
61. Hró bjartsson A, Gøtzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001; 344:1594-1602.
62. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. J Intern Med 2004; 256:91-100.
63. Meissner KI, Distel H, Mitzdorf U. Evidence for placebo effects on physical but not on biochemical outcome parameters: a review of clinical trials. BMC Med (in press).
64. Linde K, Witt CM, Streng A, et al. The impact of patient expectations on outcomes in four randomized controlled trials of acupuncture in patients with chronic pain. Pain 2007; 128:264-271.
65. Benedetti F, Arduino C, Costa S, et al. Loss of expectation-related mechanisms in Alzheimer's disease makes analgesic therapies less effective. Pain 2006; 121:133-144.
66. Ondo WG. Placebo response in Parkinson trials using patient diaries: sites do matter. Clin Neuropharmacol 2007; 30:301-304.
67. Talley NJ, Locke GR, Lahr BD, et al. Predictors of the placebo response in functional dyspepsia. Aliment Pharmacol Ther 2006; 23:923-936.
68. Enck P, Vinson B, Malfertheiner P, Klosterhalfen S. Placebo response in a functional dyspepsia drug trial: reanalysed. Gut 2007; 56 (Suppl. III):A8.
69. Evans KR, Sills T, Wunderlich GR, McDonald HP. Worsening of depressive symptoms prior to randomization in clinical trials: a possible screen for placebo responders? J Psychiatr Res 2004; 38:437-444.
70. Stein DJ, Baldwin DS, Dolberg OT, et al. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry 2006; 67:1741-1746.
71. Niklson I, Edrich P, Verdru P. Identifying baseline characteristics of placebo responders versus nonresponders in randomized double-blind trials of refractory partial-onset seizures. Epileptic Disord 2006; 8:37-44.